Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Solid Tumors 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Colorectal Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Spondylitis, Ankylosing 1Respiratory Tract Infections 1Respiratory Distress Syndrome 1Pneumonia 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Myelodysplastic Syndromes 1Mesothelioma 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1COVID-19 1Arthritis, Rheumatoid 1

Interventions

tocilizumab 1ceftolozane, tazobactam drug combination 1Observation 1Nebulizers and Vaporizers 1Lidocaine 1Immunoglobulin G 1Disulfides 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Pneumonia × tocilizumab × Clear all
NCT04370834 2025-02-04

Tocilizumab for Patients With Cancer and COVID-19 Disease

National Cancer Institute (NCI)

Phase 2 Terminated
1 enrolled 10 charts
Other hematologic neoplasm

Pneumonia, Respiratory Distress Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡